
CASE STUDY
Uncover what keeps GLP-1 patients on therapy, and what doesn’t
In this case study, a pharmaceutical manufacturer used real-world semaglutide data from HealthVerity Marketplace to understand GLP-1 persistence, adherence, and measurable outcomes over two years. By analyzing nearly 3.9 million patients, the team uncovered where attrition occurs and why long-term effectiveness is difficult to measure without complete longitudinal visibility.
Explore how the pharma company was able to:
- Quantify real-world GLP-1 persistence and adherence at scale
- Identify key drop-off points across the patient journey
- Evaluate measurable outcomes using linked closed claims and EHR data
